Europe Spinal Muscular Atrophy Treatment Market Size, Share & Industry Trends Analysis Report By Type (Type 1, Type 2, Type 3 and Type 4), By Route of Administration, By Treatment Type (Drug and Gene Therapy), By Drug Type, By Country and Growth Forecast, 2022 - 2028

The Europe Spinal Muscular Atrophy Treatment Market would witness market growth of 18.1% CAGR during the forecast period (2022-2028).

Depending on the shape and kind of SMA, the prognosis varies. Certain kinds are lethal if left untreated. Long periods of stability may be apparent in a person, but without therapy, improvement cannot be anticipated. While some SMA patients pass away in infancy, others can survive into adolescence or early adulthood.

For infants with SMA Type I, the majority pass away within the initial two years. The prognosis for average lifespan or independent walking or standing in individuals with SMA Type II approximately coincides with the age at which symptoms first appear, older children typically have less serious symptoms. Although the average lifespan is decreased, some people survive into adolescence or early adulthood. With proper treatment, some affected people may live normal lives.

People who have spinal muscular atrophy (SMA) don't create enough survival motor neuron (SMN) protein because of a mutation in the survival motor neuron gene 1 (SMN1). The motor neuron cells weaken and finally die if this protein is absent. Debilitating and sometimes deadly muscular weakness results from this. Increasing the body's supply of the survival motor neuron protein is one method of treating SMA.

This region has been active for some time in propagating awareness and understanding of SMA. Seven non-profit national patient organizations working in the SMA and neuromuscular illness fields came together to form the organization SMA Europe. It has expanded through time to include 13 full members. No medication for the management of SMA was licensed or in the clinical trial stage when the organization was established in 2007.

The Germany market dominated the Europe Spinal Muscular Atrophy Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $737.8 million by 2028. The UK market is anticipated to grow at a CAGR of 17.1% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 19% during (2022 - 2028).

Based on Type, the market is segmented into Type 1, Type 2, Type 3 and Type 4. Based on Route of Administration, the market is segmented into Injection and Oral. Based on Treatment Type, the market is segmented into Drug and Gene Therapy. Based on Drug Type, the market is segmented into Spinraza, Zolgensma (AVXS-101), Evrysdi and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Free Valuable Insights: The Global Spinal Muscular Atrophy Treatment Market will Hit $11.4 Billion by 2028, at a CAGR of 17.8%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)

Scope of the Study

Market Segments Covered in the Report:

By Type

• Type 1
• Type 2
• Type 3
• Type 4

By Route of Administration

• Injection
• Oral

By Treatment Type

• Drug
  • Spinraza
  • Zolgensma (AVXS-101)
  • Evrysdi
  • Others
• Gene Therapy

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Biogen, Inc.
• Novartis AG
• Ionis Pharmaceuticals, Inc.
• PTC Therapeutics, Inc.
• NMD Pharma A/S
• Scholar Rock, Inc. (Scholar Rock Holding Corporation)
• Cytokinetics, Inc.
• Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
• Astellas Pharma, Inc.
• F.Hoffmann-La Roche Ltd. (Genentech, Inc.)

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Spinal Muscular Atrophy Market, by Type
1.4.2 Europe Spinal Muscular Atrophy Market, by Route of Administration
1.4.3 Europe Spinal Muscular Atrophy Market, by Treatment Type
1.4.4 Europe Spinal Muscular Atrophy Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Strategies Deployed in Spinal Muscular Atrophy Market

Chapter 4. Europe Spinal Muscular Atrophy Treatment Market by Type
4.1 Europe Type 1 Market by Country
4.2 Europe Type 2 Market by Country
4.3 Europe Type 3 Market by Country
4.4 Europe Type 4 Market by Country

Chapter 5. Europe Spinal Muscular Atrophy Treatment Market by Route of Administration
5.1 Europe Injection Market by Country
5.2 Europe Oral Market by Country

Chapter 6. Europe Spinal Muscular Atrophy Treatment Market by Treatment Type
6.1 Europe Drug Market by Country
6.2 Europe Spinal Muscular Atrophy Treatment Market by Drug Type
6.2.1 Europe Spinraza Market by Country
6.2.2 Europe Zolgensma (AVXS-101) Market by Country
6.2.3 Europe Evrysdi Market by Country
6.2.4 Europe Others Market by Country
6.3 Europe Gene Therapy Market by Country

Chapter 7. Europe Spinal Muscular Atrophy Treatment Market by Country
7.1 Germany Spinal Muscular Atrophy Treatment Market
7.1.1 Germany Spinal Muscular Atrophy Treatment Market by Type
7.1.2 Germany Spinal Muscular Atrophy Treatment Market by Route of Administration
7.1.3 Germany Spinal Muscular Atrophy Treatment Market by Treatment Type
7.1.3.1 Germany Spinal Muscular Atrophy Treatment Market by Drug Type
7.2 UK Spinal Muscular Atrophy Treatment Market
7.2.1 UK Spinal Muscular Atrophy Treatment Market by Type
7.2.2 UK Spinal Muscular Atrophy Treatment Market by Route of Administration
7.2.3 UK Spinal Muscular Atrophy Treatment Market by Treatment Type
7.2.3.1 UK Spinal Muscular Atrophy Treatment Market by Drug Type
7.3 France Spinal Muscular Atrophy Treatment Market
7.3.1 France Spinal Muscular Atrophy Treatment Market by Type
7.3.2 France Spinal Muscular Atrophy Treatment Market by Route of Administration
7.3.3 France Spinal Muscular Atrophy Treatment Market by Treatment Type
7.3.3.1 France Spinal Muscular Atrophy Treatment Market by Drug Type
7.4 Russia Spinal Muscular Atrophy Treatment Market
7.4.1 Russia Spinal Muscular Atrophy Treatment Market by Type
7.4.2 Russia Spinal Muscular Atrophy Treatment Market by Route of Administration
7.4.3 Russia Spinal Muscular Atrophy Treatment Market by Treatment Type
7.4.3.1 Russia Spinal Muscular Atrophy Treatment Market by Drug Type
7.5 Spain Spinal Muscular Atrophy Treatment Market
7.5.1 Spain Spinal Muscular Atrophy Treatment Market by Type
7.5.2 Spain Spinal Muscular Atrophy Treatment Market by Route of Administration
7.5.3 Spain Spinal Muscular Atrophy Treatment Market by Treatment Type
7.5.3.1 Spain Spinal Muscular Atrophy Treatment Market by Drug Type
7.6 Italy Spinal Muscular Atrophy Treatment Market
7.6.1 Italy Spinal Muscular Atrophy Treatment Market by Type
7.6.2 Italy Spinal Muscular Atrophy Treatment Market by Route of Administration
7.6.3 Italy Spinal Muscular Atrophy Treatment Market by Treatment Type
7.6.3.1 Italy Spinal Muscular Atrophy Treatment Market by Drug Type
7.7 Rest of Europe Spinal Muscular Atrophy Treatment Market
7.7.1 Rest of Europe Spinal Muscular Atrophy Treatment Market by Type
7.7.2 Rest of Europe Spinal Muscular Atrophy Treatment Market by Route of Administration
7.7.3 Rest of Europe Spinal Muscular Atrophy Treatment Market by Treatment Type
7.7.3.1 Rest of Europe Spinal Muscular Atrophy Treatment Market by Drug Type

Chapter 8. Company Profiles
8.1 PTC Therapeutics, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.1.5.3 Approvals and Trials:
8.2 F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Approvals and Trials:
8.2.5.2 Acquisition and Mergers:
8.3 Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Novartis AG
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.4.5.2 Acquisition and Mergers:
8.5 Ionis Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expenses
8.5.4 Recent strategies and developments:
8.5.4.1 Acquisition and Mergers:
8.6 Scholar Rock, Inc. (Scholar Rock Holding Corporation)
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.7 Cytokinetics, Incorporated
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Research & Development Expenses
8.8 Astellas Pharma, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.9 Biogen, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.10. NMD Pharma A/S
8.10.1 Company Overview
8.10.2 Recent strategies and developments:
8.10.2.1 Geographical Expansions:

TABLE 1 Europe Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 2 Europe Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 3 Europe Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 4 Europe Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 5 Europe Type 1 Market by Country, 2018 - 2021, USD Million
TABLE 6 Europe Type 1 Market by Country, 2022 - 2028, USD Million
TABLE 7 Europe Type 2 Market by Country, 2018 - 2021, USD Million
TABLE 8 Europe Type 2 Market by Country, 2022 - 2028, USD Million
TABLE 9 Europe Type 3 Market by Country, 2018 - 2021, USD Million
TABLE 10 Europe Type 3 Market by Country, 2022 - 2028, USD Million
TABLE 11 Europe Type 4 Market by Country, 2018 - 2021, USD Million
TABLE 12 Europe Type 4 Market by Country, 2022 - 2028, USD Million
TABLE 13 Europe Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 14 Europe Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 15 Europe Injection Market by Country, 2018 - 2021, USD Million
TABLE 16 Europe Injection Market by Country, 2022 - 2028, USD Million
TABLE 17 Europe Oral Market by Country, 2018 - 2021, USD Million
TABLE 18 Europe Oral Market by Country, 2022 - 2028, USD Million
TABLE 19 Europe Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 20 Europe Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 21 Europe Drug Market by Country, 2018 - 2021, USD Million
TABLE 22 Europe Drug Market by Country, 2022 - 2028, USD Million
TABLE 23 Europe Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 24 Europe Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 25 Europe Spinraza Market by Country, 2018 - 2021, USD Million
TABLE 26 Europe Spinraza Market by Country, 2022 - 2028, USD Million
TABLE 27 Europe Zolgensma (AVXS-101) Market by Country, 2018 - 2021, USD Million
TABLE 28 Europe Zolgensma (AVXS-101) Market by Country, 2022 - 2028, USD Million
TABLE 29 Europe Evrysdi Market by Country, 2018 - 2021, USD Million
TABLE 30 Europe Evrysdi Market by Country, 2022 - 2028, USD Million
TABLE 31 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 32 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 33 Europe Gene Therapy Market by Country, 2018 - 2021, USD Million
TABLE 34 Europe Gene Therapy Market by Country, 2022 - 2028, USD Million
TABLE 35 Europe Spinal Muscular Atrophy Treatment Market by Country, 2018 - 2021, USD Million
TABLE 36 Europe Spinal Muscular Atrophy Treatment Market by Country, 2022 - 2028, USD Million
TABLE 37 Germany Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 38 Germany Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 39 Germany Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 40 Germany Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 41 Germany Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 42 Germany Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 43 Germany Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 44 Germany Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 45 Germany Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 46 Germany Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 47 UK Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 48 UK Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 49 UK Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 50 UK Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 51 UK Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 52 UK Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 53 UK Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 54 UK Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 55 UK Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 56 UK Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 57 France Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 58 France Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 59 France Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 60 France Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 61 France Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 62 France Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 63 France Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 64 France Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 65 France Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 66 France Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 67 Russia Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 68 Russia Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 69 Russia Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 70 Russia Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 71 Russia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 72 Russia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 73 Russia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 74 Russia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 75 Russia Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 76 Russia Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 77 Spain Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 78 Spain Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 79 Spain Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 80 Spain Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 81 Spain Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 82 Spain Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 83 Spain Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 84 Spain Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 85 Spain Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 86 Spain Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 87 Italy Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 88 Italy Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 89 Italy Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 90 Italy Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 91 Italy Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 92 Italy Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 93 Italy Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 94 Italy Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 95 Italy Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 96 Italy Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 97 Rest of Europe Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 98 Rest of Europe Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 99 Rest of Europe Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 100 Rest of Europe Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 101 Rest of Europe Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 102 Rest of Europe Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 103 Rest of Europe Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 104 Rest of Europe Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 105 Rest of Europe Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 106 Rest of Europe Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 107 Key Information – PTC Therapeutics, Inc.
TABLE 108 key information – F. Hoffmann-La Roche Ltd.
TABLE 109 Key Information – Biohaven Pharmaceutical Holding Company Ltd.
TABLE 110 Key Information – Novartis AG
TABLE 111 Key information – Ionis Pharmaceuticals, Inc.
TABLE 112 Key Information – Scholar Rock, Inc.
TABLE 113 Key Information – CYTOKINETICS, INCORPORATED
TABLE 114 key information – Astellas Pharma, Inc.
TABLE 115 Key Information – Biogen, Inc.
TABLE 116 Key Information – nmd pharma a/s

List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: PTC Therapeutics, Inc.